Lagipeg 3750IU Injection

About

Lagipeg 3750IU Injection is a pegylated form of granulocyte colony-stimulating factor (G-CSF), a naturally occurring cytokine that plays a pivotal role in regulating the production, maturation, and release of neutrophils from the bone marrow. Its primary function is to stimulate the proliferation, differentiation, and activation of neutrophil precursors. The innovative pegylation process significantly extends the half-life of the G-CSF molecule in the body, allowing for a more convenient, less frequent dosing schedule compared to non-pegylated forms. Lagipeg is specifically indicated to reduce the incidence of febrile neutropenia in patients with non-myeloid malignancies who are receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. By rapidly increasing neutrophil counts, it effectively helps to mitigate the severe risk of infection, a common and dangerous complication of chemotherapy.

Uses

• Prevention of febrile neutropenia in chemotherapy patients
• Reduction of infection risk in myelosuppressed patients
• Mobilization of hematopoietic stem cells for transplantation
• Treatment of severe chronic neutropenia (off-label in some cases)

Directions For Use

Administer as a subcutaneous injection, typically once per chemotherapy cycle, at least 24 hours after chemotherapy. Follow healthcare provider's instructions.

Benefits

• Significantly reduces the incidence and duration of febrile neutropenia.
• Lowers the risk of life-threatening infections during chemotherapy.
• Pegylated formulation allows for single-dose per cycle convenience.
• Supports completion of planned chemotherapy regimens.
• Improves patient safety and reduces hospitalizations.
• Stimulates rapid recovery of neutrophil counts.

Side Effects

• Bone pain
• Myalgia (muscle pain)
• Headache
• Nausea
• Fatigue
• Injection site reactions
• Splenomegaly (enlarged spleen)
• Allergic reactions (rare)
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)
• Leukocytosis (high white blood cell count)
• Capillary leak syndrome (rare)

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but general health recommendations apply.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus. Consult a doctor.
• Breastfeeding - Unknown if excreted in human milk. Exercise caution when administered to a breastfeeding woman.
• Liver - No specific dose adjustment is typically required for patients with hepatic impairment.
• Kidney - No specific dose adjustment is typically required for patients with renal impairment, but monitor closely.
• Lung - Rarely, serious pulmonary adverse reactions, including ARDS, have been reported. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.